Health CarePharmaceuticals & Biotechnology
  • Price (GBX)1,358.61
  • Today's Change14.61 / 1.09%
  • Shares traded11.66k
  • 1 Year change+65.89%
  • Beta0.6501
Data delayed at least 20 minutes, as of Jul 29 2021 09:32 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Financials data is unavailable for this security.

Inc stmt in GBPIncome statement in GBPView more

Year on year Oxford BioMedica PLC grew revenues 36.95% from 64.06m to 87.73m while net income improved from a loss of 16.07m to a smaller loss of 6.25m.
Gross margin52.52%
Net profit margin-7.12%
Operating margin-6.49%
Return on assets-4.07%
Return on equity-6.63%
Return on investment-5.54%
More ▼

Cash flow in GBPView more

In 2020, Oxford BioMedica PLC increased its cash reserves by 187.77%, or 30.50m. Cash Flow from Financing totalled 38.19m or 43.53% of revenues. In addition the company generated 3.12m in cash from operations while cash used for investing totalled 10.80m.
Cash flow per share0.045
Price/Cash flow per share308.86
Book value per share1.37
Tangible book value per share1.37
More ▼

Balance sheet in GBPView more

Oxford BioMedica PLC has a Debt to Total Capital ratio of 10.94%, a higher figure than the previous year's 10.46%.
Current ratio2.06
Quick ratio1.93
Total debt/total equity0.1228
Total debt/total capital0.1094
More ▼
Refinitiv, an LSEG business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.